Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

George Cardoza Biography and Net Worth

Insider of NeoGenomics

George Cardoza began his career with NeoGenomics in 2009, serving as the company’s Chief Financial Officer until his appointment to President of Pharma Services in 2018. Prior to NeoGenomics, Prior to that, he was the Chief Financial Officer at Protocol Integrated Direct Marketing. Mr. Cardoza spent fifteen years with Quest Diagnostics, including years when it was still part of Corning Inc. With Corning Inc. he worked with the Corning Life Sciences Division, which did several acquisitions in the Pharma services space. These acquisitions formed the pieces of Covance, which Corning spun out at the same time as Quest in 1996. Mr. Cardoza received his Bachelor’s Degree in Finance and Accounting from Syracuse University and his M.B.A. from Michigan State University.

What is George Cardoza's net worth?: The estimated net worth of George Cardoza is at least $2.86 million as of June 2nd, 2021. Mr. Cardoza owns 207,879 shares of NeoGenomics stock worth more than $2,862,494 as of April 18th. This net worth estimate does not reflect any other assets that Mr. Cardoza may own. Learn More about George Cardoza's net worth.
How do I contact George Cardoza?: The corporate mailing address for Mr. Cardoza and other NeoGenomics executives is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. NeoGenomics can also be reached via phone at (239) 768-0600 and via email at [email protected]. Learn More on George Cardoza's contact information.
Has George Cardoza been buying or selling shares of NeoGenomics?: George Cardoza has not been actively trading shares of NeoGenomics during the last quarter. Most recently, George Cardoza sold 169,230 shares of the business's stock in a transaction on Wednesday, June 2nd. The shares were sold at an average price of $40.39, for a transaction totalling $6,835,199.70. Following the completion of the sale, the insider now directly owns 207,879 shares of the company's stock, valued at $8,396,232.81. Learn More on George Cardoza's trading history.
Who are NeoGenomics' active insiders?: NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), and Robert Shovlin (Insider). Learn More on NeoGenomics' active insiders.
Are insiders buying or selling shares of NeoGenomics?: During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 5,256 shares worth more than $87,784.43. The most recent insider tranaction occured on February, 15th when General Counsel Alicia C Olivo sold 2,587 shares worth more than $38,701.52. Insiders at NeoGenomics own 1.3% of the company. Learn More about insider trades at NeoGenomics.
Information on this page was last updated on 2/15/2024.

George Cardoza Insider Trading History at NeoGenomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/2/2021	Sell	169,230	$40.39	$6,835,199.70	207,879
11/24/2020	Sell	52,926	$45.19	$2,391,725.94	423,828
8/6/2020	Sell	82,500	$39.35	$3,246,375.00	433,402
11/12/2019	Sell	19,444	$23.15	$450,128.60	345,275
11/6/2019	Sell	51,556	$22.82	$1,176,507.92	356,387
5/3/2019	Sell	151,676	$22.82	$3,461,246.32	452,507
3/11/2016	Sell	32,000	$6.83	$218,560.00	221,089
11/26/2014	Sell	60,000	$4.28	$256,800.00
12/9/2013	Sell	20,000	$3.66	$73,200.00

George Cardoza Buying and Selling Activity at NeoGenomics

NeoGenomics Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Range

Now: $13.77

$13.62

$14.09

50 Day Range

MA: $15.15

$13.68

$16.79

2 Week Range

Now: $13.77

$11.03

$21.22

Volume

913,517 shs

Average Volume

904,194 shs

Market Capitalization

$1.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad